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There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide
and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently
available. In rodents, liraglutide activated the GLP-1 receptors on C-cells, causing an increased incidence of C-cell neoplasia.
Animal experiments with monkeys demonstrated no increase in calcitonin release and no C-cell proliferation after long-term
liraglutide administration. Longitudinal 2-year data from clinical trials do not support any signiﬁcant risk for the activation or
growth of C-cell cancer in humans in response to liraglutide. However, an analysis of the FDA adverse event reporting system
database suggested an increased risk for thyroid cancer associated with exenatide after its marketing. Noticeably, a recent study
discovered that GLP-1 receptor could also be expressed in human papillary thyroid carcinomas (PTC), but the impact of GLP-1
analogs on PTC is not known. Therefore, GLP-1 analogs might increase the risk of thyroid C-cell pathology in rodents, but its risk
in humans awaits conﬁrmation. Since GLP-1 receptor is also expressed in PTC besides C-cells, it is important to investigate the
actions of GLP-1 on diﬀerent subtypes of thyroid cancer in the future.
1.Introduction
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
releasedaftermealsbyLcellsintheileum[1].Itincreasesthe
secretion of insulin from the pancreas in a glucose-depend-
entmannerandsuppressesthesecretionofglucagon,acoun-
ter-hormone to insulin [2]. There are two GLP-1-mimetic
drugs currently approved for clinical use to treat type-
2 diabetes, that is, exenatide and liraglutide [3, 4]. Exenatide
is the ﬁrst GLP-1 receptor agonist approved in April 2005
for the treatment of type-2 diabetes mellitus. It is a 39-
amino acid peptide with 53% amino acid homology to full-
length GLP-1 [4]. With elimination by glomerular ﬁltration
[5] and a mean half-life of 3.3–4 hours [6], exenatide has to
be injected subcutaneous twice a day. On January 25, 2010,
the FDA approved liraglutide, a GLP-1 receptor agonist that
can be injected once daily to improve glycemic control in
adults with type-2 diabetes [3, 4]. Liraglutide is a long-acting
GLP-1 analog with one amino acid substitution (Arg34Lys)
and an attachment of a C-16-free-fatty acid derivative via
a glutamol spacer to Lys26 [4]. These modiﬁcations lead to
slower absorption rate from injection site, higher binding
aﬃnity to albumin, and a plasma half-life of 11–13 hours
[7–9]. While GLP-1 analogs can eﬃciently reduce blood
glucose level in patients with type-2 diabetes [3, 4], they may
potentially have adverse eﬀects on thyroid glands because
GLP-1 receptors are expressed in thyroid glands of humans
[10] as well as in those of rodents [11]. In preclinical animal
studies, rodents treated with liraglutide would have a higher
incidence of C-cell tumor formation and focal hyperplasia
[12, 13]. It is possible that long-term exposure to GLP-1
receptoragonistsinhumansmayalsoinduceC-cellneoplasia
since GLP-1 receptors are expressed in the human thyroid
glands [10].
Both the prevalence and incidence of diabetes have been
increasing dramatically in recent decades, especially in the
Asian people [14]. Diabetes is also one of the leading causes
o fd e a t hn o w a d a y s[ 15]. The link between diabetes and2 Experimental Diabetes Research
cancers has become a great concern recently, and the use of
antidiabetic drugs may partially contribute to such an
increased cancer risk in the diabetic patients [16–25]. For
examples some clinical trials have suggested an association
between pioglitazone and bladder cancer [26, 27]. In this
paper, we reviewed experimental studies, controlled clinical
trials, and observational human studies currently available
on the association between GLP-1 analogs and thyroid
cancer.
2. ExperimentalIn Vitro and
AnimalStudiesinRodents
Calcitonin,ahormonesecretedbythyroidCcells,isregarded
as an important clinical biomarker for C-cell diseases such
as medullary thyroid carcinoma (MTC) and hereditary C-
cell hyperplasia because of its high sensitivity and speciﬁcity
[28–30]. Several in vitro studies employing rat thyroid C-cell
lines and thyroid tissues have demonstrated that activation
of the GLP-1 receptor leads to calcitonin secretion, which is
attenuated by the GLP-1 receptor antagonist exendin (9–39)
[31, 32]. The functional eﬀect of GLP-1 receptor agonists on
rat C-cell lines was investigated by Knudsen et al. [11]. They
found that GLP-1 receptor agonists elicited calcitonin release
and calcitonin gene expression in a dose-dependent manner
in rodent C cells. GLP-1 receptor agonists, including native
GLP-1, exenatide, and liraglutide, activated rodent thyroid
C cells to release calcitonin in a GLP-1 receptor-dependent
manner.
Inadditiontotheinvitrostudies,Knudsenetal.designed
animal experiments to study the development of C-cell
hyperplasia and tumor formation after long-term dosing
with GLP-1 receptor agonists in rodents [11]. The incidences
ofboth C-cell hyperplasiaand C-celltumor formationat104
weeks increased in a dose-dependent manner and reached
statistical signiﬁcance. The minimum doses of liraglutide
to cause a statistically signiﬁcant increase in the incidence
of C-cell hyperplasia were 0.25mg/kg/day in rats and
0.2mg/kg/day in mice. Both doses were 2-fold greater than
the equivalent human dose of 1.8mg/day [11, 12]. The
minimum doses to induce a signiﬁcant increase in C-cell
tumor formation in rats and mice were 0.075mg/kg/day
and 1.0mg/kg/day, respectively; the dose in rats
(0.075mg/kg/day) was equivalent to the dose recommended
for treatment of type-2 diabetes in humans [11, 12]. On
the other hand, C-cell tumors occurred in mice receiving
a daily dose of liraglutide that was 10-fold greater than the
corresponding human dose [11, 12]. Of note, in 2-year
studies involving wild-type mice, dose-dependent C-cell
hyperplasia and neoplasia developed only at doses that also
caused increased calcitonin levels [11]. Together, in vitro
and in vivo experiments have demonstrated that long-term
GLP-1 receptor activation is associated with increased
calcitonin gene transcription and subsequently with C-cell
proliferation and tumor formation in both rats and mice.
Madsen et al. [33] documented that C-cell hyperplasia
andcalcitoninreleaseassociatedwithGLP-1agonistsinwild-
type mice were GLP-1-receptor dependent. Besides, C-cell
eﬀects seen in mice were not associated with the activation
of the rearranged-during-transfection (RET) protoonco-
gene. GLP-1 activates the mammalian target of rapamycin
(mTOR) pathway by stimulating the production of cAMP.
ActivationofmTORinturnresultsindownstreamphospho-
rylation of ribosome S6. In contrast, these eﬀects were not
observed in GLP-1-receptor knock-out mice.
3. ExperimentalIn Vitro and
AnimalStudiesinPrimates
In addition to their experiments in rodents, Knudsen et al.
[11] investigated the eﬀect of GLP-1 receptor agonists on
human TT C cells and on nonhuman primates (cynomolgus
monkeys). In contrast to the results in rodents, GLP-1
receptor agonists did not stimulate calcitonin release in
human TT C cells. The expression of GLP-1 receptor in
human TT C cells was very low, and the corresponding
mRNA transcripts were 14- to 21-fold lower than in rat C
cells. Furthermore, in vivo animal studies with cynomolgus
monkeys demonstrated no calcitonin release and no eﬀects
on the relative C-cell fraction in the thyroid gland or C-cell
proliferation in monkeys after up to 87 weeks dosing with
liraglutide at 5.0mg/kg/day. This liraglutide dose was up to
60-fold greater than the highest dose recommended for the
treatment of type-2 diabetes.
4.HumanClinicalTrialsand
Epidemiologic Studies
Additionally, a series of clinical trials in over 5,000 patients
with either diabetes or nondiabetic obesity was presented by
Heged¨ us et al. [34]. In all trials, subjects were randomized to
receive liraglutide at doses ranging from 0.6 to 3.0mg, active
comparator, and/or placebo. Calcitonin concentration was
monitored at baseline and at 12-week intervals, thereafter,
in all subjects enrolled in 8 phase-3 clinical trials (the
liraglutide eﬀect and action in diabetes (LEAD) trials 1–6,
and 2 phase-3 trials in Japanese subjects) and in 1 phase-
2 trial with nondiabetic obese subjects. These trials had
intervention phases of 20 to 104 weeks. When combining
data from these 9 clinical studies, there was no consistent
change in calcitonin levels over time (up to 104 weeks)
with any dose of liraglutide or between treatment groups in
the proportion of patients whose calcitonin levels increased
above a clinically relevant cut-oﬀ value of 20pg/mL. The
proportion of subjects switching to a higher calcitonin
category, deﬁned by the upper normal range (UNR; <UNR,
UNR-2UNR, ≥2UNR) or by potential calcitonin signals of
20, 50, and 100ng/L for C-cell abnormalities (<20ng/L, 20
to <50ng/L, 50 to <100ng/L, and ≥100ng/L), was low and
did not diﬀer between the liraglutide and active comparator
groups. In the LEAD-6 trial [3], the calcitonin responses
to distinct GLP-1 receptor agonists (liragutide 1.8mg once
daily versus exenatide 10µg twice daily) were compared.
No diﬀerence was seen in estimated geometric mean cal-
citonin over 26 weeks between the 2 groups. In the trial
with nondiabetic obese subjects, treatment groups receivingExperimental Diabetes Research 3
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a higher liraglutide dose (1.2–3mg/day) were compared
with those receiving orlistat (360mg/day) or placebo. The
estimated geometric mean calcitonin levels over 52 weeks
remained at the low end of the normal range in all treatment
groups. Regarding clinical adverse events related to C cells,
6 subjects were found to have histologically documented C-
cell hyperplasia with identical prevalence in the liraglutide
and nonliraglutide groups. One case of MTC was described
in a subject who was not treated with liraglutide. Although
there were ﬂuctuations in calcitonin levels among these 7
subjects during the trial periods, no consistent pattern was
discovered. Taking together, these data do not support any
signiﬁcant risk for the activation or growth of C cells in
humans in response to GLP-1 receptor agonists over the 2-
year period.
Although GLP-1 receptor stimulation induced calcitonin
release and C-cell proliferation in rodents, these eﬀects
were not observed in primates [11], implying possible
species-speciﬁc diﬀerences in GLP-1 receptor expression and
activation in the thyroid. Computer-assisted cell counting
in sections stained immunohistochemically for calcitonin
revealed that the C-cell densities in thyroid glands from
cynomolgus monkeys and humans were comparable, and
more importantly, that the C-cell densities in thyroid glands
in mice and rats were 22- and 45-fold higher, respectively,
than that in humans [11].
5. GLP-1Receptor ExpressioninThyroid
TumorsDerivedfromFollicularCellsand
Its FunctionalSigniﬁcance
Recently, Gier et al. [10] examined thyroid tissue samples
procured at surgery from individuals with C-cell hyperplasia
and those with MTC for the presence of GLP-1 receptor
expression using immunocytochemical techniques. C-cells
within relatively normal tissue without any hyperplasia or
neoplastic changes were also evaluated for GLP-1 receptor
expression. In this study, calcitonin-expressing C cells were
immunoreactive for GLP-1 receptor in 33% (5/15), 91%
(10/11), and 100% (9/9) of individuals with normal thyroid
lobes, MTC, and C-cell hyperplasia, respectively. There was
no immunoreactivity for either calcitonin or the GLP-1
receptor in normal thyroid follicles identiﬁed in the same
sections. Furthermore, there was no correlation between
the extent of GLP-1 receptor immunoreactivity and either
tumor size or plasma calcitonin concentrations. Moreover,
the expression of calcitonin and GLP-1 receptors was
investigated in thyroid tissues obtained from 17 individuals
with papillary thyroid cancer (PTC). PTC cells were negative
for calcitonin. But GLP-1 receptor immunoreactivity was
unexpectedly present in PTC cells in 3 of the 17 (18%)
cases. In other words, the GLP-1 receptor is not expressed
in normal thyroid follicular cells but may be aberrantly
present in a subset of PTCs derived from follicular cells.
The functional signiﬁcance of these ﬁndings has not yet
been ascertained. PTC is the most common malignancy
of the thyroid, constituting approximately 50–90% of thy-
roid malignancies worldwide [35]. Thus, GLP-1 receptor
immunopositivity in a subset of PTC lesions is likely to
be of greater epidemiological signiﬁcance than in C-cell
neoplasms. Elashoﬀ et al. [36] examined the FDA adverse
event reporting system (AERS) database for thyroid cancer
in association with exenatide, another human GLP-1 analog.
The reported event rate for thyroid cancer was 4.73-fold
greater in patients treated with exenatide compared to the
control drug, rosiglitazone (P = 4 × 10
−3). Although it is
impossible to know the thyroid cancer subtypes reported
in FDA AERS database, these ﬁndings indicate that it is
important to carefully monitor individuals exposed to long-
term pharmacological GLP-1 analogs for any increased
incidenceofthyroidmalignancies.Inaddition,moredetailed
future investigation into the actions of GLP-1 on each
subtype of thyroid cancers, especially PTC, is required.
6. Conclusion
Table 1 summarizes the ﬁndings on thyroid cancers after
dosing with GLP-1 analogs from experimental studies, con-
trolled clinical trials and observational studies (Table 1).
Data from studies in rodents suggested that GLP-1 analogs
were associated with an increased risk of thyroid C-cell
hyperplasia and C-cell tumors. On the other hand, animal
experimentswithmonkeysdidnotshowincreasedcalcitonin
release or proliferation of C-cells in thyroid glands after
chronic administration of liraglutide. Longitudinal data
from clinical trials have not demonstrated a causal associ-
ation between GLP-1 analogs and thyroid C-cell pathology
overa2-yearperiod.However,long-termobservationalstud-
ies are required to monitor such a potential risk in human. It
is worth noting that a subset of human PTC expresses GLP-1
receptors. The FDA AERS database supported an increased
risk of thyroid cancer associated with exenatide. It is urgent
toinvestigatetheactionsofGLP-1oneachsubtypeofthyroid
cancers, especially PTC, in the future. Besides, caution is
warranted in the use of this class of agents, especially in
individuals with a history of thyroid cancer.
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